Recombinant HB-EGF reduced the sensitivity of ALK-rearranged lung cancer cells to lorlatinib, whereas EGFR knockdown restored the sensitivity of A925L and H2228 cells to lorlatinib in the presence of HB-EGF (Fig. 2e). The gene discussed is ALK; the disease is lung carcinoma.